SCHEMBL273973

SCHEMBL273973

COc1ccc(Oc2cccc(Cl)c2C=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
LMNA P02545 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP2C9 P11712 1/20 0.57
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 1/20 0.50
HTT P42858 4/20 0.47
HPGD P15428 2/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
CYP2A6 P11509 1/20 0.43
MAPK1 P28482 1/20 0.43
MAOB P27338 2/20 0.42
NFE2L2 Q16236 2/20 0.42
POLB P06746 1/20 0.41
RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13815386 0.87 ALDH1A1 (0.50) ALDH1A1LMNACYP1A2CYP2C19CYP2C9
SCHEMBL11154583 0.87 KMT2A (0.53) ALDH1A1LMNACYP1A2CYP2C19CYP2C9
SCHEMBL7770741 0.85 ALDH1A1 (0.55) ALDH1A1LMNACYP1A2CYP2C19CYP2C9
SCHEMBL459037 0.83 ALDH1A1 (0.61) ALDH1A1CYP1A2CYP2C19CYP2C9KMT2A
SCHEMBL2562522 0.79 PARP10 (0.53) ALDH1A1LMNAKMT2ATDP1MEN1
SCHEMBL14649873 0.77 L3MBTL1 (0.61) ALDH1A1LMNACYP1A2CYP2C19CYP2C9
SCHEMBL25942502 0.76 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2C19KMT2ATDP1
SCHEMBL9683719 0.75 NPSR1 (0.55) ALDH1A1CYP1A2CYP2C19CYP2C9KMT2A
SCHEMBL14582406 0.75 TTR (0.57) ALDH1A1LMNACYP1A2CYP2C19CYP2C9
SCHEMBL2813748 0.74 MEN1 (0.46) ALDH1A1LMNACYP2C19CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT ALDH1A1 138/4885LMNA 549/4885CYP1A2 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.